-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since Biogen's new Alzheimer's disease drug Aduhelm was approved by the FDA on June 7, its controversy has never stopped
Recently, the situation has become more foggy.
The OIG investigation is one of the most severe civil investigations conducted against federal agencies
Earlier, calls for an OIG investigation focused on the close relationship between Billy Dunn, head of the FDA's neuroscience department, and Biogen executives
Facing the current situation, many scholars expressed their support
Professor Steven Joffe of the Perelman School of Medicine at the University of Pennsylvania said: "It is very important to understand how this decision came about and the relationship behind it.
Aduhelm launched by Biogen aims to solve the root cause of Alzheimer's disease.
Nowadays, we do not know whether there is a shady behind the FDA's approval of Aduhelm's listing, but people's criticism of the approval of this new drug is not limited to whether it has scientific basis, but extends to the FDA's internal approval process and loopholes
